Literature DB >> 26680136

Resuscitative endovascular balloon occlusion of the aorta (REBOA): Comparison with immediate transfusion following massive hemorrhage in swine.

Timothy S Park1, Andriy I Batchinsky, Slava M Belenkiy, Bryan S Jordan, William L Baker, Corina N Necsoiu, James K Aden, Michael A Dubick, Leopoldo C Cancio.   

Abstract

BACKGROUND: Resuscitative endovascular balloon occlusion of the aorta (REBOA) is less invasive than emergency department thoracotomy for the treatment of massive hemorrhage. We evaluated the effects of REBOA on carotid blood flow (Qcarotid) in a porcine model of massive hemorrhage. We hypothesized that REBOA restores Qcarotid faster than reinfusion of blood.
METHODS: Spontaneously breathing sedated Sinclair pigs underwent exponential hemorrhage of 65% total blood volume in 1 hour. They were randomized into three groups. Positive control (PC, n = 7) underwent immediate transfusion of shed blood. REBOA (n = 21) received a novel 7 Fr ER-REBOA catheter (Pryor Medical, Arvada, CO) placed into aortic Zone 1 via a femoral artery introducer for 30 minutes or 60 minutes, with transfusion either after deflation or midway through inflation. Negative control (n = 7) received no resuscitation. Qcarotid was recorded continuously using an ultrasonic flow probe. Survival and time between Qcarotid, min and both a stable maximal value (Qcarotid, max) and restoration of baseline flow (Qcarotid, new BL) were compared by Kaplan-Meier analysis.
RESULTS: Median time to Qcarotid, max was 3.0 minutes in the REBOA group versus 9.6 minutes in the control group (p = 0.006). Median time to Qcarotid, new BL was 6.0 minutes in the REBOA group versus 20.5 minutes in the PC group (p = 0.11). Slope of the linear regression between Qcarotid, min and Qcarotid, new BL was 16.7 in REBOA and 10.4 in PC (p = 0.31). Four-hour survival was 95% (20 of 21) in the REBOA group versus 71% (5 of 7) in the PC group (p = 0.06) and 0% in the negative control group.
CONCLUSION: REBOA resulted in the restoration of Qcarotid ("cerebrovascular resuscitation") at least as rapidly as retransfusion of shed blood, with equivalent 4-hour survival. Further studies of REBOA, to include mitigation of end-organ effects and longer follow-up, are needed.

Entities:  

Mesh:

Year:  2015        PMID: 26680136     DOI: 10.1097/TA.0000000000000877

Source DB:  PubMed          Journal:  J Trauma Acute Care Surg        ISSN: 2163-0755            Impact factor:   3.313


  11 in total

1.  The effect of resuscitative endovascular balloon occlusion of the aorta, partial aortic occlusion and aggressive blood transfusion on traumatic brain injury in a swine multiple injuries model.

Authors:  M Austin Johnson; Timothy K Williams; Sarah-Ashley E Ferencz; Anders J Davidson; Rachel M Russo; William T O'Brien; Joseph M Galante; J Kevin Grayson; Lucas P Neff
Journal:  J Trauma Acute Care Surg       Date:  2017-07       Impact factor: 3.313

Review 2.  [Resuscitative endovascular balloon occlusion of the aorta : Option for incompressible trunk bleeding?]

Authors:  J Knapp; M Bernhard; T Haltmeier; D Bieler; B Hossfeld; M Kulla
Journal:  Anaesthesist       Date:  2018-04       Impact factor: 1.041

3.  Non-invasive Dual-Channel Broadband Diffuse Optical Spectroscopy of Massive Hemorrhage and Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) in Swine.

Authors:  Jesse H Lam; Thomas D O'Sullivan; Tim S Park; Jae H Choi; Robert V Warren; Wen-Pin Chen; Christine E McLaren; Leopoldo C Cancio; Andriy I Batchinsky; Bruce J Tromberg
Journal:  Mil Med       Date:  2018-03-01       Impact factor: 1.437

4.  Directly Cooling Gut Prevents Mortality in the Rat Model of Reboa Management of Lethal Hemorrhage.

Authors:  Chunli Liu; Dong Yuan; Robert Crawford; Rajabrata Sarkar; Bingren Hu
Journal:  Shock       Date:  2021-11-01       Impact factor: 3.533

Review 5.  Pelvic trauma: WSES classification and guidelines.

Authors:  Federico Coccolini; Philip F Stahel; Giulia Montori; Walter Biffl; Tal M Horer; Fausto Catena; Yoram Kluger; Ernest E Moore; Andrew B Peitzman; Rao Ivatury; Raul Coimbra; Gustavo Pereira Fraga; Bruno Pereira; Sandro Rizoli; Andrew Kirkpatrick; Ari Leppaniemi; Roberto Manfredi; Stefano Magnone; Osvaldo Chiara; Leonardo Solaini; Marco Ceresoli; Niccolò Allievi; Catherine Arvieux; George Velmahos; Zsolt Balogh; Noel Naidoo; Dieter Weber; Fikri Abu-Zidan; Massimo Sartelli; Luca Ansaloni
Journal:  World J Emerg Surg       Date:  2017-01-18       Impact factor: 5.469

Review 6.  Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA): update and insights into current practices and future directions for research and implementation.

Authors:  Marianne A Thrailkill; Kevin H Gladin; Catherine R Thorpe; Teryn R Roberts; Jae H Choi; Kevin K Chung; Corina N Necsoiu; Todd E Rasmussen; Leopoldo C Cancio; Andriy I Batchinsky
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2021-01-06       Impact factor: 2.953

7.  Focal intra-colon cooling reduces organ injury and systemic inflammation after REBOA management of lethal hemorrhage in rats.

Authors:  Awadhesh K Arya; Kurt Hu; Lalita Subedi; Tieluo Li; Bingren Hu
Journal:  Sci Rep       Date:  2021-07-01       Impact factor: 4.379

Review 8.  Prehospital control of life-threatening truncal and junctional haemorrhage is the ultimate challenge in optimizing trauma care; a review of treatment options and their applicability in the civilian trauma setting.

Authors:  S E van Oostendorp; E C T H Tan; L M G Geeraedts
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2016-09-13       Impact factor: 2.953

9.  REBOA: is it ready for prime time?

Authors:  Jay Doucet; Raul Coimbra
Journal:  J Vasc Bras       Date:  2017 Jan-Mar

10.  Distal organ inflammation and injury after resuscitative endovascular balloon occlusion of the aorta in a porcine model of severe hemorrhagic shock.

Authors:  Yansong Li; Michael A Dubick; Zhangsheng Yang; Johnny L Barr; Brandon J Gremmer; Michael L Lucas; Corina Necsoiu; Bryan S Jordan; Andriy I Batchinsky; Leopoldo C Cancio
Journal:  PLoS One       Date:  2020-11-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.